ASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010

In this podcast, UROONCO RCC chief editor Dr. Maria Carmen Mir (ES) talks to Prof. Laurence Albiges (FR) on the abstract she recently presented at ASCO2024 - “Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomised phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection”. Prof. Albiges details the two parts of the circulating biomarker ana...